Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism. (PEITHO-2)
Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism
Sponsor: European Georges Pompidou Hospital
Terminated
1. Interim results suggested a reduction of sample size.~2. Anticipated length of enrolment period with resulting funding issues to pose a threat to the study.
Other terminated trials from European Georges Pompidou Hospital
See all terminations from European Georges Pompidou Hospital
Other Pulmonary Embolism trials with similar outcome
A PHASE4 clinical study on Pulmonary Embolism, this trial is terminated or withdrawn. The trial is conducted by European Georges Pompidou Hospital and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 4 earlier versions
-
Mar 2020 — Nov 2020 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Apr 2019 — Mar 2020 [monthly]
Recruiting PHASE4
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Georges Pompidou Hospital
- Prof. Stavros Konstantinides, MD
For direct contact, visit the study record on ClinicalTrials.gov .